OBJECTIVE: To compare differences in long-term outcome between adults with childhood-onset (age at diagnosis <18 years) systemic lupus erythematosus (SLE) and with adult-onset SLE. METHODS: Data were derived from the University of California Lupus Outcomes Study, a longitudinal cohort of 885 adult subjects with SLE (90 childhood-onset [cSLE], 795 adult-onset [aSLE]). Baseline and 1-year followup data were obtained via structured 1-hour telephone interviews conducted between 2002 and 2006. Using self-report data, differences in organ involvement and disease morbidity, current disease status and activity, past and current medication use, and number of physician visits were compared, based on age at diagnosis of SLE. RESULTS: Average disease duration for the cSLE and aSLE subgroups was 16.5 and 13.4 years, respectively, and mean age at followup was 30.5 and 49.9 years, respectively. When compared with aSLE subjects, cSLE subjects had a higher frequency of SLE-related renal disease, whereas aSLE subjects were more likely to report a history of pulmonary disease. Rates of clotting disorders, seizures, and myocardial infarction were similar between the 2 groups. At followup, cSLE subjects had lower overall disease activity, but were more likely to be taking steroids and other immunosuppressive therapies. The total number of yearly physician visits was similar between the 2 groups, although cSLE subjects had a higher number of nephrology visits. CONCLUSION: This study demonstrates important differences in the outcomes of patients with cSLE and aSLE, and provides important prognostic information about long-term SLE disease activity and treatment.
OBJECTIVE: To compare differences in long-term outcome between adults with childhood-onset (age at diagnosis <18 years) systemic lupus erythematosus (SLE) and with adult-onset SLE. METHODS: Data were derived from the University of California Lupus Outcomes Study, a longitudinal cohort of 885 adult subjects with SLE (90 childhood-onset [cSLE], 795 adult-onset [aSLE]). Baseline and 1-year followup data were obtained via structured 1-hour telephone interviews conducted between 2002 and 2006. Using self-report data, differences in organ involvement and disease morbidity, current disease status and activity, past and current medication use, and number of physician visits were compared, based on age at diagnosis of SLE. RESULTS: Average disease duration for the cSLE and aSLE subgroups was 16.5 and 13.4 years, respectively, and mean age at followup was 30.5 and 49.9 years, respectively. When compared with aSLE subjects, cSLE subjects had a higher frequency of SLE-related renal disease, whereas aSLE subjects were more likely to report a history of pulmonary disease. Rates of clotting disorders, seizures, and myocardial infarction were similar between the 2 groups. At followup, cSLE subjects had lower overall disease activity, but were more likely to be taking steroids and other immunosuppressive therapies. The total number of yearly physician visits was similar between the 2 groups, although cSLE subjects had a higher number of nephrology visits. CONCLUSION: This study demonstrates important differences in the outcomes of patients with cSLE and aSLE, and provides important prognostic information about long-term SLE disease activity and treatment.
Authors: A J Swaak; H G van den Brink; R J Smeenk; K Manger; J R Kalden; S Tosi; A Marchesoni; Z Domljan; B Rozman; D Logar; G Pokorny; L Kovacs; A Kovacs; P G Vlachoyiannopoulos; H M Moutsopoulos; H Chwalinska-Sadowska; B Dratwianka; E Kiss; N Cikes; A Branimir; M Schneider; R Fischer; S Bombardieri; M Mosca; J S Smolen Journal: Rheumatology (Oxford) Date: 1999-10 Impact factor: 7.580
Authors: E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester Journal: Arthritis Rheum Date: 1982-11
Authors: Paivi M Miettunen; Oliva Ortiz-Alvarez; Ross E Petty; Rolando Cimaz; Peter N Malleson; David A Cabral; Stephanie Ensworth; Lori B Tucker Journal: J Rheumatol Date: 2004-08 Impact factor: 4.666
Authors: E W Karlson; L H Daltroy; C Rivest; R Ramsey-Goldman; E A Wright; A J Partridge; M H Liang; P R Fortin Journal: Lupus Date: 2003 Impact factor: 2.911
Authors: L B Tucker; A G Uribe; M Fernández; L M Vilá; G McGwin; M Apte; B J Fessler; H M Bastian; J D Reveille; G S Alarcón Journal: Lupus Date: 2008-04 Impact factor: 2.911
Authors: Aimee O Hersh; Laura Trupin; Jinoos Yazdany; Peter Panopalis; Laura Julian; Patricia Katz; Lindsey A Criswell; Edward Yelin Journal: Arthritis Care Res (Hoboken) Date: 2010-08 Impact factor: 4.794
Authors: Deborah M Levy; Christine A Peschken; Lori B Tucker; Gaëlle Chédeville; Adam M Huber; Janet E Pope; Earl D Silverman Journal: Arthritis Care Res (Hoboken) Date: 2013-01 Impact factor: 4.794
Authors: Edward Yelin; Chris Tonner; Laura Trupin; Pantelis Panopalis; Jinoos Yazdany; Laura Julian; Patricia Katz; Lindsey A Criswell Journal: Arthritis Rheum Date: 2009-02-15
Authors: Asma Al Rasbi; Eiman Abdalla; Rabab Sultan; Nasreen Abdullah; Juma Al Kaabi; Ibrahim Al-Zakwani; Reem Abdwani Journal: Rheumatol Int Date: 2018-05-02 Impact factor: 2.631